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HermanskyePudlak syndrome (HPS) is an autosomal recessive disorder characterized by oculocutaneous
albinism, bleeding tendency, and lysosomal accumulation of ceroid-like material, with occasional
development of interstitial pneumonia (IP). Nine genetically distinct subtypes of HPS are known in
humans; IP develops primarily in types 1 and 4. Most reported cases of HPS with IP are type 1, and there
are no published reports of type 4 in Japanese individuals. A 58-year-old man with congenital oculo-
cutaneous albinism and progressive dyspnea for 1 month was admitted to our hospital. We administered
high-dose corticosteroids on the basis of a diagnosis of acute exacerbation of interstitial pneumonia.
Respiratory symptoms and the ﬁndings of high-resolution computed tomography (CT) showed
improvement. He was diagnosed with HPS type 4 with interstitial pneumonia on the basis of gene
analysis. He has been receiving pirfenidone for 1 year and his condition is stable. This is the ﬁrst report on
the use of pirfenidone for HPS with IP caused by a novel mutation in the HPS4 gene. We conclude that
HPS should be suspected in patients with albinism and interstitial pneumonia. High-dose corticosteroid
treatment may be useful in cases of acute exacerbation of interstitial pneumonia due to HPS-4, and
pirfenidone may be useful and well tolerated in patients with HPS-4.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
HermanskyePudlak syndrome (HPS) is a genetic multisystem
disorder characterized by oculocutaneous albinism, a bleeding
tendency secondary to platelet dysfunction, and lysosomal ceroid
accumulation.1 Ceroid, which accumulates sporadically and slowly
in the lungs, is not crucial for a diagnosis of HPS, but primarily
accounts for the signiﬁcant associated morbidity. Pulmonary
ﬁbrosis, usually manifesting in the third and fourth decades of life,
accounts for premature death in 50% of HPS patients, which
generally occurs by the ﬁfth decade.2,3
Nine different genes cause HPS in humans.4,5 Among them, the
HPS-1 gene shows the highest frequency of mutation. HPS-1 mu-
tation represents the classical disease, which manifests with all the
typical complications of HPS. HPS-4 disease is considered to
resemble HPS-1, but only a few case of HPS-4 have been reported.6e
9 HPS-1 and HPS-4 individuals show the greatest degree of pul-
monary involvement, with an estimated 80% of HPS-1 subtypes
afﬂicted.6,10 Here, we report a case of HPS presenting with inter-
stitial pneumonia and exhibiting a novel HPS-4 gene mutation.: þ81 96 351 4323.
umamoto.jp, sakata.4415@
-NC-ND license.2. Case report
A 58-year-old man was admitted to our hospital because of
progressive dyspnea. He had experienced shortness of breath for
years, but had been well until 4 weeks earlier. He showed
congenital albinism, amblyopia, and photodermatosis, but had
received no previous medication for the condition. He was a
massager, drank distilled spirits about 250ml/day, and had smoked
occasionally. The patient’s family history revealed that his parents
were cousins. There is no history of albinism in his family, but his
father died of pulmonary disease at approximately 50 years.
On admission, body temperature was normal range, pulse rate
was 95 beats per minute, blood pressure was 110/60 mmHg, res-
piratory rate was 25 w 30 breaths per minute, and oxygen satu-
ration was 82% in ambient air, increasing to 95% with oxygen
supplementation (3 l) by nasal cannula. Physical examination on
admission revealed blond hair, blond body hair, pale white skin,
and erythema on the upper and lower extremities and neck (Fig. 1).
The patient had amblyopia, strabismus, and horizontal nystagmus.
Fine crackles in the bilateral lower lung ﬁelds were detected, but
heart sounds were normal. He had neither clubbed ﬁnger nor
edema. The results of abdominal and neurological examinations
were normal.
Laboratory results on admission are shown in Table 1. Although
the patient was anemic, white blood cell and platelet counts were
normal, and congealing ﬁbrinogenolysis was also normal. Blood
Fig. 1. Patient’s appearance. Left, note the blond hair and albinism. Right, the blond body hair and erythema at sites of exposure to sunlight.
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lated carbohydrate antigen (KL-6) levels. Chest radiography
showed bilateral volume loss, and the lower lobes showed domi-
nantly diffuse linear and reticular opacity with ground-glass
opacity in both lung ﬁelds. Chest CT showed bilateral diffuse
ground-glass opacity associated with mild traction bronchiectasis
and reticulation which was consistent with acute exacerbation on
chronic ﬁbrosing interstitial pneumonia (Figs. 2 and 3). A trans-
thoracic echocardiogram showed mild right ventricular hypo-
kinesis, but left ventricular function was normal. There were no
clinical signs of pulmonary infection.
We diagnosed acute exacerbation of interstitial pneumonia, and
treated with high-dose corticosteroid (methylprednisolone,
1000mg/day for three days followed by oral prednisone at a dose of
40 mg/day). His clinical symptoms and ﬁndings on high-resolution
CT slowly improved; therefore, additional corticosteroid pulse
therapy and pirfenidonewere administered for ﬁbrosing interstitial
pneumonia. Subsequently, his breathing condition, clinical marker
levels, and chest imaging results stabilized, but he needed long-
term oxygen therapy.
Because the patient had interstitial pneumonia with albinism,
we investigated the possibility of HPS. Therefore, bone marrow
biopsy, platelet aggregation test, and genetic diagnosis were per-
formed to diagnose HPS. A platelet aggregation test revealed a lack
of secondary wave aggregation with normal ﬁrst aggregation ofTable 1
Laboratory ﬁndings on admission.
Blood analysis Blood gas analysis (room air)
WBC 6300/mL pH 7.476
Hb 10.8 g/dL PaO2 40.8 mmHg
Ht 37.3% PaCO2 35.6 mmHg
Plt 28.6  104/mL HCO3 25.9 mmol/L
PT (%) 76.7%
APTT (%) 72.2% Pulmonary function test (analyzed on day8)
AT III 91% VC 2.28 L
FDP 3.0 mg/mL %VC 62%
Bleeding time 3 min FEV1.0 2.06 L
BUN 7.7 mg/dL FEV1.0%-G 93.7%
CRE 0.89 mg/dL (%DLCO was not examined because of respiratory
insufﬁciency)AST 37 IU/L
ALT 36 IU/L Platelet aggregation test
LDH 371 IU/L ADP (3.0 mM) 76%
ESR 1 h 50 mm, 2 h 73 mm Collagen (2.0 mg/mL) 44%
CRP 1.82 mg/dL
b-D-glucan < 5.0 pg/mL
IgG 1383 mg/dL
IgA 740 mg/dL
IgM 87 mg/dL
BNP 78.5 pg/mL
SP-D 168 ng/mL
KL-6 1550 U/mL
ANA ()
PR3-ANCA, MPO-ANCA ()ADP (Table 1). Bone marrow biopsy showed that macrophages
contained a ceroid-like material (Fig. 4). We performed mutation
analysis of HPS-1 (GenBank accession no. NM_000195.3) and HPS-4
(GenBank accession no. NM_022081.4) gene (Supplementary File).
We identiﬁed a novel mutation, c.1858C > T (p.Q620X), in HPS4
homozygously in the patient and heterozygously in his mother, his
sister and his daughter (Fig. 5). The diagnosis of HPS-4 was
conﬁrmed by this gene analysis.
The corticosteroid dose was gradually tapered and then dis-
continued as the patient’s condition became stable. Pirfenidone
dosage was increased gradually without harmful adverse effects.
Although chest CT performed after one year of treatment demon-
strated progression of bilateral diffuse ground-glass opacity with
mild traction bronchiectasis (Fig. 3), response to therapy was
considered “stable” according to the ATS/ERS criteria by using
pulmonary functional indices (Table 2).11
3. Discussion
We present a rare case of HPS-4 with interstitial pneumonia.
High-dose corticosteroid treatment was effective for acute exacer-
bation of IP and pirfenidone has been used for 1 year.
HPS is a rare autosomal recessive disorder. It is characterized by
oculocutaneous albinism, platelet dysfunction, and accumulation of
ceroid-like materials and is associated with interstitial pneumonia.
HPS is common only in northwest Puerto Rico. However, it is
extremely rare in other regions, occurring with a prevalence of 1 in
500,000e1,000,000 persons.12 Among these cases, nearly allFig. 2. Chest radiograph showing bilateral volume loss and lower lobes with domi-
nantly diffuse linear and reticular opacity, with ground-glass opacity in both lung
ﬁelds.
Fig. 3. AeB, CT scan of right lung at time of admission. CeD, same slices of right lung 2 months later, showing improvement of ground-glass opacity and reticulonodular pattern as
the result of treatment. EeF, same slices of right lung at 1 year after admission, showing gradual progression of disease.
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never been reported in Japan.
The pathogenesis of HPS has been currently investigated, but
many parts remain unexplained.13e17
The discovery of the HPS-4 subtype in 2002 was followed by
examination of the HPS-4 mouse mutant.8 Bachli et al. have re-
ported the only case of HPS-4 with IP.9 According to previous re-
ports, the phenotype of HPS-4 is similar to that of HPS-1, and the
mean age of onset of pulmonary symptoms in patients with mu-
tations in the HPS1 gene is about 30e40 years.18 In our case, onset
was relatively late and severity of ﬁbrosis was moderate. Anderson
et al. reported clinical features of 7 patients with documented HPS-Fig. 4. Bone marrow biopsy showing macrophages containing ceroid-like materials.4 mutations, ranging in age from 3 to 61 years.6 Three of the 7
patients had restrictive lung disease; one had severe pulmonary
ﬁbrosis and died of lung disease. According to Avila et al., patients
with mutations in the HPS-1 gene had more severe lung disease
than patients without HPS-1 genemutations.3 The clinical course of
HPS-4 may be slightly different from that of HPS-1 based on the
previous reports and ours.
Regarding the treatment of interstitial pneumonia associated
with HPS, corticosteroids or other immunosuppressive drugs
generally have not been effective,18 but there have been no trials
examining the efﬁcacy of steroid treatment. In our case, respiratory
status and ﬁndings on CT scans clearly improved in the ﬁrst 2Fig. 5. Sequence analysis of exon 13 in HPS4 gene using genomic DNA samples from
the patient and his mother reveals the novel mutation, c.1858C > T (p.Q620X), ho-
mozygously in the patient and heterozygously in his mother. The mutation was also
detected in his sister and his daughter (data not shown).
Table 2
Clinical course over 1 year.
Blood analysis
Reference
range
Admission 3 Months 6 Months 9 Months 12 Months
LDH (IU/L) 112e213 371 367 358 318 330
KL-6 (U/mL) <500 1550 1250 2520 1790 1620
Pulmonary function tests
Day 8 4 Months 8 Months 12 Months
VC (L) 2.28 2.71 2.27 2.37
%DLCO (%) No data 36.9 25.2 28.2
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the patient’s improvement after the initial deterioration of IP. High-
dose steroid therapy should be considered as a treatment option in
these situations, because there is no alternative effective therapy
during an acute exacerbation of IP.
Subsequently, we added pirfenidone and gradually reduced the
corticosteroid dose. Gahl et al. reported that pirfenidone may slow
the progression of pulmonary ﬁbrosis due to HPS-1.19 On the other
hand, recently, a small number of randomized controlled trials has
been published that did not show slowing of decline in pulmonary
function in small numbers.20 Thus, the utility of pirfenidone for HPS
with IP remains controversial. Nevertheless, to our knowledge, ours
is the ﬁrst case in which pirfenidone was used for genetically
proven HPS-4. Further study is neededwhether pirfenidonemay be
effective in interstitial pneumonia associated with HPS. Finally, the
only deﬁnitive treatment for pulmonary ﬁbrosis related to HPS-1 is
lung transplantation,21 but this was not an option in our case due to
the patient’s age.
When encountering a patient with oculocutaneous albinism
with interstitial pneumonia, HPS should be considered. Although
lung biopsy could not be performed in our patient because of res-
piratory insufﬁciency, it is a preferred diagnostic technique to
reveal characteristic macrophages containing ceroid pigments and
foamy swelling of pneumocytes. Further investigation of genetic
analysis and enrollment of these cases is indispensable for appro-
priate treatment strategies.
In conclusion, our ﬁndings suggest that HPS should be sus-
pected in patients with albinism and interstitial pneumonia.
High-dose corticosteroid may be useful in cases of acute exacer-
bation of interstitial pneumonia due to HPS-4, and pirfenidone
might be effective in treatment for progressive HPS-4 pulmonary
ﬁbrosis.Acknowledgment
We greatly acknowledge the assistance of Takihiro Kamio in the
Division of PathologyMedicine, Saiseikai Kumamoto Hospital. Gene
analysis of this case was performed by Department of Dermatology,
Nagoya University Graduate School of Medicine.Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.rmcr.2013.04.002.
References
1. Hermansky F, Pudlak P. Albinism associated with hemorrhagic diathesis and
unusual pigmented reticular cells in the bone marrow. Blood 1959;14:162e9.
2. Shotelersuk V, Dell’Angelica EC, Hartnell L, Bonifacino JS, Gahl WA. A new
variant of HermanskyePudlak syndrome due to mutations in a gene respon-
sible for vesicle formation. Am J Med 2000;108:423e7.
3. Gahl WA, Brantly M, Troendle J, Avila NA, Padua A, Montalvo C, et al. Effect of
pirfenidone on the pulmonary ﬁbrosis of HermanskyePudlak syndrome. Mol
Genet Metab 2002;76:234e42.
4. Huizing M, Gahl WA. Disorders of vesicles of lysosomal lineage: the Herman-
skyePudlak syndromes. Curr Mol Med 2002;2:451e67.
5. Anderson PD, Huizing M, Claassen DA, White J, Gahl WA. HermanskyePudlak
syndrome type4 (HPS-4): clinical and molecular characteristics. Hum Genet
2003;113:10e7.
6. Wei ML. HermanskyePudlak syndrome: a disease of protein trafﬁcking and
organelle function. Pigment Cell Res 2006;19:19e42.
7. Cullinane AR, Curry JA, Carmona-Rivera C, Summers CG, Ciccone C, Cardillo ND,
et al. A BLOC-1 mutation screen reveals that PLDN is mutated in Hermanskye
Pudlak syndrome type 9. Am J Hum Genet 2011;88:778e87.
8. Gahl WA, Brantly M, Kaiser-Kupfer MI, Iwata F, Hazelwood S, Shotelersuk V,
et al. Genetic defects and clinical characteristics of patients with a form of
oculocutaneous albinism (HermanskyePudlak syndrome). N Eng J Med
1998;338:1258e64.
9. Suzuki T, Li W, Zhang Q, Karim A, Novak EK, Sviderskaya EV, et al. Hermanskye
Pudlak syndrome is caused by mutations in HPS4, the human homolog of the
mouse light ear gene. Nat Genet 2003;30:321e4.
10. Bachli EB, Brack T, Eppler E, Stallmach T, Trüeb RM, Huizing M, et al. Her-
manskyePudlak syndrome type 4 in a patient from Sri Lanka with pulmonary
ﬁbrosis. Am J Med Genet A 2004;127A:201e7.
11. Idiopathic pulmonary ﬁbrosis: diagnosis and treatment: international
consensus statement. American Thoracic Society (ATS), and European Respi-
ratory Society (ERS). Am J Respir Crit Care Med 2000;161:646e64.
12. Witkop CJ, Nuñez Babcock M, Rao GH, Gaudier F, Summers CG, Shanahan F,
et al. Albinism and HermanskyePudlak syndrome in Puerto Rico. Bol Asoc Med
P R 1990;82:333e9.
13. Huizing M, Helip-Wooley A, Westbroek W, Gunay-Aygun M, Gahl WA. Disor-
ders of lysosome-related organelle biogenesis: clinical and molecular genetics.
Annu Rev Genomics Hum Genet 2008;9:359e86.
14. Falcón-Pérez JM, Nazarian R, Sabatti C, Dell’Angelica EC. Distribution and dy-
namics of Lamp1-containing endocytic organelles in ﬁbroblasts deﬁcient in
BLOC-3. J Cell Sci 2005;118:5243e55.
15. Young LR, Pasula R, Gulleman PM, Deutsch GH, McCormack FX. Susceptibility
of HermanskyePudlak mice to bleomycin-induced type II cell apoptosis and
ﬁbrosis. Am J Respir Cell Mol Biol 2007;37:67e74.
16. Yoshioka Y, Kumasaka T, Ishidoh K, Kominami E, Mitani K, Hosokawa Y, et al.
Inﬂammatory response and cathepsins in silica-exposed HermanskyePudlak
syndrome model pale ear mice. Pathol Int 2004;54:322e31.
17. Mahavadi P, Korfei M, Henneke I, Liebisch G, Schmitz G, Gochuico BR, et al.
Epithelial stress and apoptosis underlie HermanskyePudlak syndrome-
associated interstitial pneumonia. Am J Respir Crit Care Med 2010;182:207e19.
18. Pierson DM, Ionescu D, Qing G, Yonan AM, Parkinson K, Colby TC, et al. Pul-
monary ﬁbrosis in HermanskyePudlak syndrome: a case report and review.
Respiration 2006;73:382e95.
19. O’Brien K, Troendle J, Gochuico BR, Markello TC, Salas J, Cardona H, et al. Pir-
fenidone for the treatment of HermanskyePudlak syndrome pulmonary
ﬁbrosis. Mol Genet Metab 2011;103:128e34.
20. Lederer DJ, Kawut SM, Sonett JR, Vakiani E, Seward Jr SL, White JG, et al.
Successful bilateral lung transplantation for pulmonary ﬁbrosis associated with
the HermanskyePudlak syndrome. J Heart Lung Transplant 2005;24:1697e9.
21. Avila NA, Brantly M, Premkumar A, Huizing M, Dwyer A, Gahl WA. Herman-
skyePudlak Syndrome: radiography and CT of the chest compared with pul-
monary function tests and genetic studies. Am J Roentgenol 2002;179:887e92.
